NCT04982237 - A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer | Biotech Hunter

Enrollment

445

Participants

Timeline

Start Date

August 27, 2021

Primary Completion Date

April 1, 2025

Study Completion Date

December 30, 2025

Conditions

Cervical Cancer

Interventions

BIOLOGICAL

AK104

IV infusion

DRUG

paclitaxel

IV infusion

DRUG

carboplatin

iv infusion

DRUG

cisplatin

iv infusion

DRUG

bevacizumab

iv infusion

DRUG

Placebo

iv infusion

Trial Locations (5)

Fudan University Shanghai Cancer Center, Shanghai

Women's Hospital School Of Medicine Zhejiang University, Hangzhou

Zhejiang Cancer Hospital, Hangzhou

Anhui Provincial Hospital, Hefei

The Second Affiliated Hospital,Anhui Medical University, Hefei